...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of Thrombosis and Thrombolysis >Benefits of pharmacological facilitation with glycoprotein IIb-IIIa inhibitors in diabetic patients undergoing primary angioplasty for STEMI. A subanalysis of the EGYPT cooperation
【24h】

Benefits of pharmacological facilitation with glycoprotein IIb-IIIa inhibitors in diabetic patients undergoing primary angioplasty for STEMI. A subanalysis of the EGYPT cooperation

机译：糖蛋白IIb-IIIa抑制剂在进行STEMI初次血管成形术的糖尿病患者中药理作用的益处。埃及合作的子分析

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The Early Glycoprotein IIb-IIIa inhibitors in Primary angioplasty (EGYPT) cooperation aimed at evaluating, by pooling individual patient’s data of randomized trials, the benefits of pharmacological facilitation with Gp IIb-IIIa inhibitors among STEMI patients undergoing primary angioplasty. In the current study we analyze the benefits of early Gp IIb-IIIa inhibitors in diabetic patients. The literature was scanned by formal searches of electronic databases (MEDLINE, EMBASE) from January 1990 to October 2007. We examined all randomized trials on facilitation by early administration of Gp IIb-IIIa inhibitors in STEMI. No language restrictions were enforced. Individual patients’ data were obtained from 11 out of 13 trials, including 1,662 patients. Diabetes was present in 281 (16.9%). Early Gp IIb-IIIa inhibitors were associated with improved preprocedural TIMI 3 flow (26.0% vs. 13.1%, P = 0.006), postprocedural TIMI 3 flow (90.1% vs. 75.0%, P = 0.18), MBG 3 (40.8% vs. 30.4%, P = 0.004), and less distal embolization (11.6% vs. 20.8%, P = 0.05). However, early Gp IIb-IIIa inhibitors did not significantly reduce mortality (8.3% vs. 9.5%, P = 0.64). This meta-analysis shows that pharmacological facilitation with early administration of Gp IIb-IIIa inhibitors in STEMI patients with diabetes undergoing primary angioplasty, is associated with significant benefits in terms of preprocedural and postprocedural TIMI flow, improved myocardial perfusion, without significant benefits in mortality.
机译：早期糖原蛋白IIb-IIIa抑制剂在原发性血管成形术（EGYPT）合作中的目的在于，通过汇总个别患者的随机试验数据，评估在进行原发性血管成形术的STEMI患者中使用Gp IIb-IIIa抑制剂进行药理简化的益处。在本研究中，我们分析了早期Gp IIb-IIIa抑制剂对糖尿病患者的益处。从1990年1月至2007年10月，通过电子数据库（MEDLINE，EMBASE）的正式搜索对文献进行了扫描。我们检查了STEMI中早期给予Gp IIb-IIIa抑制剂对促进作用的所有随机试验。没有语言限制。从13个试验中的11个获得个体患者的数据，包括1,662名患者。糖尿病患者为281（16.9％）。早期的Gp IIb-IIIa抑制剂与改善的术前TIMI 3流量（26.0％比13.1％，P = 0.006），术后TIMI 3流量（90.1％比75.0％，P = 0.18），MBG 3（40.8％vs. 30.4％，P = 0.004），远端栓塞较少（11.6％vs. 20.8％，P = 0.05）。但是，早期的Gp IIb-IIIa抑制剂并未显着降低死亡率（8.3％对9.5％，P = 0.64）。这项荟萃分析显示，在接受原发性血管成形术的STEMI糖尿病患者中，早期服用Gp IIb-IIIa抑制剂的药理学促进作用与术前和术后TIMI流量显着相关，改善了心肌灌注，但对死亡率无显着益处。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号